Neuroinflammation and subarachnoid hemorrhage: a revised look at the literature

Sai Sriram\textsuperscript{1}, Christopher Cutler\textsuperscript{2}, Mohammed Azab\textsuperscript{3}, Ramya Reddy\textsuperscript{1}, Rodeania Peart\textsuperscript{1}, Brandon Lucke-Wold\textsuperscript{1,*}

\textsuperscript{1}Department of Neurosurgery, University of Florida, Gainesville, FL, U.S.A.
\textsuperscript{2}Rosalind Franklin University of Medicine and Science, Chicago, IL, U.S.A.
\textsuperscript{3}Department of Biomolecular Sciences, Boise State University, Boise, ID, U.S.A.

Abstract

A key topic for aneurysmal subarachnoid hemorrhage is neuroinflammation. Neuroinflammation can predispose to aneurysm formation and rupture. Neuroinflammation can also result from the blood breakdown products after aneurysm rupture. Recent evidence has shown that perpetual neuroinflammation can contribute to vasospasm and hydrocephalus. Targeting neuroinflammation is a novel mechanism for preventing subsequent neurologic sequelae. In this review, we highlight the pathophysiology of aneurysm formation, the neuroinflammatory surge after rupture including the involved cytokines, and ultimately tie in the contributory clinical relevance. In the last sections, we look at the pre-clinical data and novel avenues for further discovery. This paper will be a useful resource to both the clinician and scientific investigator.

Keywords

neuroinflammation; subarachnoid hemorrhage; treatment approach; aneurysm formation

Introduction

Aneurysmal subarachnoid hemorrhage (aSAH) is a significant source of morbidity and mortality resulting from vessel damage with an overall prevalence of 3.2\% [1]. Aneurysm rupture can lead to brain damage, hydrocephalus, dramatic cognitive decline, and vasospasm [2]. A key feature in aSAH pathophysiology is inflammation. Neuroinflammation and aSAH are intricately related with a mutually causal relationship: inflammatory changes both lead to formation of aSAH and are evident in the period following subarachnoid hemorrhage.

*Corresponding to: Brandon Lucke-Wold, Department of Neurosurgery, University of Florida, Gainesville, McKnight Brain Institute Room L2-100, 149 South Newell Drive, Gainesville, Florida 32611, U.S.A. Brandon.Lucke-Wold@neurosurgery.ufl.edu.

Competing interests

The authors declare no conflicts of interest.
Neuroinflammation causes aSAH

There are several mechanisms that contribute to aSAH progression (Figure 1). Increased oxidative stress in the period preceding aneurysm formation, for one, is thought to disrupt the endothelial regulation of vessel tone, compounding the issue of hemodynamic wall stress [3]. Certain genetic conditions such as polycystic kidney disease, which leads to impaired smooth muscle and blood vessel strength [4], and connective tissue disorders such as Ehlers-Danlos, which impair the integrity of collagen [5], also lead to aSAH progression. Despite this, neuroinflammation occupies a central role in the initiation of aSAH, directly leading to endothelial and smooth muscle dysfunction as well as vessel wall damage, which we describe here.

Several inflammatory changes have been observed to contribute to aneurysm formation. Namely, elevated hemodynamic shear stress has been shown to activate the pro-inflammatory transcription factor-κB (NF-κB) pathway in endothelial cells [6, 7]. NF-κB is a key inflammatory transcription factor which, in turn, engenders an inflammatory pro-death autophagy state in endothelial cells and vascular smooth muscle cells, leading to the thinning of vessel walls and eventual aneurysm rupture [8]. NF-κB has also been implicated in the inhibition of procollagen expression in the aSAH, leading to further weakening of vessel walls [9]. Further, NF-κB promotes macrophage recruitment by upregulating cell adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) [10]. In turn, these macrophages infiltrate into the vessel wall and secrete more pro-inflammatory cytokines, setting up a vicious inflammatory positive feedback loop that causes vessel ballooning [11]. For example, microglia, the resident macrophages of the central nervous system, can adopt a pro-inflammatory M1 configuration or a neuroprotective M2 configuration [12]. Aneurysm formation is thought to be mediated by polarization of microglia towards the M1 phenotype. Proinflammatory neutrophils are thought to play a role in this polarization, since antibodies against CXCL1 – a neutrophil recruitment chemokine – reduce the M1 phenotype [13]. Complement activation has also been observed as an inflammatory change preceding aSAH, as membrane attack complex (MAC) localization to saccular aneurysm has been observed both prior and following rupture [14]. Clearly, several inflammatory molecular pathways triggered by changes in hemodynamic flow result in damage to the cerebral vessel wall prior to rupture.

Neuroinflammation is a result of aSAH

Though inflammation is abundant in the period leading to aneurysm rupture, an increasing amount of evidence points to the inflammatory changes in the period following aneurysm rupture. Cell death markers such as caspase-3 are elevated in parenchymal and vascular cells just 10 minutes after aneurysm rupture [15], and inflammatory proteins such as high-mobility group box 1 (HMGB1) are elevated in as little as 2 hours following aSAH rupture [16], underscoring the swift response to intracranial hemorrhage. Blood brain barrier (BBB) disruption precipitated by inflammation is also a hallmark in the post-hemorrhage period and has been observed as soon as 24–48 hours after aneurysm rupture [17]. In the first 72 hours following aSAH rupture, microglia polarization into the pro-inflammatory M1 configuration has been observed [18, 19]. This microglial reaction is thought to have a temporal component. Early brain injury following aneurysm rupture is associated with this
early microglial inflammatory reaction, which precedes a later monocytic infiltration [20]. Blockade of this microglial reaction or polarization away from the M1 phenotype conveys a neuroprotective effect [21, 22]. In one study, neuronal apoptosis was avoided with microglia depletion 7 days following aneurysm rupture but was not avoided with microglia depletion 15 days following aneurysm rupture [23]. Taken together, this suggests that inflammatory agents in the early phase following aneurysm rupture are key drivers of injury.

**Current and Emerging Treatments for aSAH**

Current management of aSAH can be understood in terms of surgical and medical treatment approaches. If vessel rupture has not occurred yet, coil embolization or aneurysm clipping is a surgical option used to prevent delayed aneurysm rupture and resultant ischemia [24]. Medical management of aSAH focuses on control of hypertension and reduction of bleeding. Blood pressure control is a central theme of medical management to avoid risk of stroke and further bleeding. In fact, antihypertensives such as nimodipine may even be used in the acute period following aSAH [25]. Early endovascular clipping of ruptured aneurysms is associated with improved clinical outcome [26] and represents a surgical modality in the acute management of a ruptured SAH. Counseling to reduce pro-aneurysmal risk factors such as smoking and high alcohol intake is also part of the management regimen [25].

In addition to the current treatments for aSAH, several emerging drug candidates are poised to target neuroinflammation, removing a central mediator in the progression of brain injury after aSAH. Levosimendan, a calcium channel sensitizer, has been used for several years in the treatment of heart failure [27], though recently has been investigated for its anti-inflammatory effects which have been shown to ameliorate cerebral vasospasm following aSAH [28]. Milk fat globule epidermal growth factor 8 (MFG-E8) is a glycoprotein which mediates phagocytosis of apoptotic cells [29], that has recently been implicated in diminishing the inflammatory response [30]. One recent study employed the use of a recombinant MFG-E8 in a SAH rat model and discovered that MFG-E8 downregulated the proinflammatory HMGB1 and attenuated early brain injury caused by subarachnoid hemorrhage (SAH) [31]. Indeed, targeting the proinflammatory HMGB1 is a focus of recent work and has been shown to diminish early brain injury following SAH [32, 33]. The lipid-derived resolvins have also been investigated recently for their neuroprotective and anti-inflammatory effects following SAH rupture. Resolvin-D1 administration in a rat model of SAH not only downregulated inflammatory markers such as matrix metalloproteinase-9 (MMP-9) and ICAM-1, but it also prevented inflammatory cell infiltration and improved neurological function [34]. Taken together, these recent advances represent promising therapeutic targets in the de-escalation of the neuroinflammatory response following SAH rupture.

**Inflammatory cytokines and SAH**

Inflammatory cytokines play a key role in the pathogenesis and resolution of SAH [60]. Some, such as interleukin-1β (IL-1β), interleukin-1α (IL-1α) and TNF-α, have well defined roles in the cellular and environmental changes following SAH (Table 1). Other cytokines have shown to be elevated at various time points following the inciting event but without a
clear understanding of their actions (Table 1). Further understanding of these cytokines along with their levels and timeframes could lead to targeted therapies aimed at preventing SAH complications such as vasospasm and hydrocephalus [36, 52, 61]. Although both the timeframe [60, 61] and the levels [62] of cytokines following SAH have been studied, there remains a lack of consensus on how and when to measure these cytokines following SAH to improve clinical outcomes and develop targeted therapies [61].

Cytokines were first identified in brain injury by Giulian et al in 1986 when interleukin-1 (IL-1) was shown to be secreted by microglia to upregulate astroglia [63]. This was shortly followed by a study showing microglia secreting TNFα under certain pathological states [64]. Aloisi et al then demonstrated that astrocyte secretion of IL-1β leads to the secretion of other cytokines such as IL-6, IL-8, IL-1β, and colony stimulating factors. To a lesser degree astrocytes also were shown to secrete TNFα leading to the release of similar cytokines [65]. From there, IL-6 was shown to be elevated in cerebrospinal fluid (CSF) following SAH in 1993 [35]. IL-6 and IL-8 were both thought to be important immunomodulators following SAH [36]. Kikuchi et al postulated that IL-6 functions as an important vasoconstrictor in post-SAH vasospasm [36]. This hypothesis was supported by further studies showing that higher levels of IL-6 and TNFα increased the risk of vasospasm following SAH [52]. IL-6 has also been implicated in delayed ischemic deficits [45] and as a general marker for post-SAH complications [53, 55]. Cytokine IL-1 was shown to mediate fever, leukocytosis, and NO synthesis following SAH [37]. Mathiesen T et al also demonstrated that high CSF cytokine levels correlated with brain damage [37]. Although individual cytokines had been studied following SAH, Takizawa et al were first to demonstrate the cascade of cytokines following SAH [41]. They found that elevated levels of CRP and TGF-β were associated with communicating hydrocephalus [41]. Fassbender et al found that both blood flow velocity and intrathecal secretion of these cytokines contributed to the compartmentalized inflammatory response following SAH [40, 66]. This compartmentalized response could also be driven by vasoconstrictors such as endothelin 1 [66]. Although astrocyte and microglial involvement was elucidated early on, only recently has the mechanism for neutrophil recruitment following SAH been understood. Coulibaly et al found that increased CSF IL-17 leads to the recruitment of neutrophils to the site of inflammation following the initial insult [60]. Other cytokines following SAH have been shown to play roles in immunosuppression such as TGF-β [41] and IL-10 [53]. Chaudhry SR et al. found that elevated IL-10 was associated with immunodepression leading to increased nosocomial infections following SAH [53]. Other cytokines play critical roles as neuroprotective factors following SAH [67].

Several papers have looked at the association of cytokine levels and outcome at various time points following SAH. Levels of IL-1ra, and TNFα have been shown to be associated with outcome in both the subacute and acute timeframes [37, 39]. Further, high CSF levels of IL-6 in the subacute timeframe has been shown to correlate with poor 3- and 6-month outcomes [39, 46, 51, 61]. Clinical use of these cytokine profiles could guide clinical decisions if standardized, but there is not yet a consensus on how or when to collect these markers in clinical practice [61].
Whether being secreted from leukocytes [66] or glial cells [63–65], cytokines play a key role in the response of the brain parenchyma following SAH. Cytokines are directly responsible for the numerous structural and chemical changes that occur minutes to months following SAH [62]. By better understanding the temporal nature and which cytokines predominate, clinicians may be better equipped to manage and prevent common complications following SAH.

**Clinical relevance**

About one third of patients with acute SAH develop ischemia caused by narrowing of the blood vessels supplying the brain [68, 69], making it one of the main causes of morbidity and mortality among patients with SAH. Proper risk prediction and adequate management of the problem reduces morbidity and mortality, but the pathogenesis of cerebral vasospasm is multifocal and not well understood. Researchers have investigated many risk factors associated with developing vasospasm such as age, sex, cigarette smoking, alcohol intake, heart disease, diabetes, and body mass index (BMI) [70, 71]. Radiological and laboratory data have also been studied to depict any correlation or risk stratification for the prediction of post SAH vasospasm [72, 73]. Symptomatic vasospasm may present with recent onset or worsening neurological insults without causes being explained by angiography [72, 74] and is defined in two ways: radiological or clinical. Radiological vasospasm is defined as narrowing of the major cerebral vessels and may be focal or diffuse [74, 75]. It starts usually on the third day after SAH and usually lasts for 2–3 weeks [74–76]. Clinical vasospasm is identified by a delayed neurologic effect and presents as a gradual loss of consciousness with focal motor and speech deficits [75].

Pathogenesis of cerebral vasospasm: The mechanism of SAH induced vasospasm is not clear. Several pathways seem to be involved in the pathogenesis of vasospasm and delayed cerebral ischemia [77]. Here, we provide an overview of these mechanisms and the updated strategies for possible therapies.

**Mechanisms involving vascular smooth muscles**

Intracellular calcium is known to regulate smooth muscle contraction [78]. In case of vasospasm, contraction of vascular smooth muscles occurs in both calcium dependent and independent manners [77]. For one, smooth muscle calcium regulation is thought to be disrupted following SAH [79]. Further, the products of blood in the subarachnoid space are suggested to stimulate G protein coupled receptors which may further increase intracellular calcium [77].

**Endothelial factors**

Endothelial cells regulate the tone of vascular smooth muscles by secreting different mediators as NO, prostacyclins and endothelins. There is a balance between vasoconstrictors and vasodilators under normal physiological conditions. The shift of this balance towards the vasoconstrictive side is thought to be highly involved in cerebral vasospasm [80]. Endothelin-1 (ET-1) is a potent natural vasoconstrictor secreted by endothelial cells, and ET-1 receptor expression is upregulated in the cerebral vessels of patients with SAH in a...
hypoxia-dependent process [81, 82]. Some clinical trials have demonstrated that endothelin-1 inhibition reversed SAH-associated decrease in cerebral blood flow [83]. The conscious trials reported that inhibition of the endothelin-1 pathway reduced the degree of vasospasm without any pronounced effect on functionality [84, 85].

**Neurogenic mechanism**

Transient global cerebral ischemia is the first pathologic insult that occurs immediately after SAH and in this case the intracranial pressure is so close to the mean arterial pressure [86]. Stimulation of the sympathetic system is most prominent at this stage resulting in catecholamine surge [87]. The catecholamine levels remain high in the blood of patients with SAH several days after the bleed and their levels correlate with poor prognosis [87, 88].

**Glymphatics role**

The lymphatic vessels within the lining of the venous sinuses of the brain [89] are also thought to contribute to vasospasm. Oxidative stress after SAH was exaggerated after cervical lymph node blockage that was observed before discovery of brain lymphatics [90]. Paravascular glymphatic channels are located close to cerebral arteries and represent a direct interface between CSF and brain interstitial environment [91]. Blood products can pass through these channels and initiate parenchymal inflammatory reactions [92]. Magnetic resonance imaging reported reduced glymphatics perfusion following acute SAH [93].

**Hydrocephalus**

Hydrocephalus is a common complication of spontaneous SAH with acute onset presenting in 15–87% of cases [25, 94], and chronic in 9–64% [95, 96]. Management of increased intracranial pressure is crucial for the survival of these patients. Early intervention using an external ventricular drain (EVD) reduces the long-term effect of blockage of CSF pathway with blood clots, however, it may complicate treatment and cause infection [97, 98].

Various mechanisms are involved in the pathogenesis of acute and chronic hydrocephalus following aneurysmal SAH. Ventricular system adhesions, abnormal CSF dynamics, and blocked arachnoid granulations are possible mechanisms [99, 100]. It is reported that fibrosis in the subarachnoid space is responsible for the pathogenesis of chronic hydrocephalus following aneurysmal SAH [101]. Various cytokines secreted by inflammatory cells recruit fibroblasts initiating a fibroproliferative reaction in the subarachnoid space [41]. Therefore, both inflammatory and fibroblastic responses are culprit in the pathogenesis of post aneurysmal SAH.

**Fibrosis involvement in hydrocephalus**

Fibrosis at the arachnoid granulations reduces CSF absorption and impairs its circulation, resulting in hydrocephalus. Levels of fibrosis promoting factors such as TGFb1 are upregulated in the CSF of patients with SAH with chronic hydrocephalus indicating a possible relation with hydrocephalus [102]. TGFb1 is the predominant profibrotic factor in the CNS and is secreted by glia and neurons [103]. A pathway involved in fibrosis is highly dependent on the activity of TGFb1 [104]. Experimental studies have shown that TGFb1 inhibition reduced the burden of hydrocephalus in rats with SAH [105].

_Clin Res Commun. Author manuscript; available in PMC 2022 July 14._
Pre-clinical findings

Several models are used for SAH including mouse, rat, rabbit, and dog models [106]. However, rat and mice models are by far the most commonly used [107]. While several rodent models are available, these models are unable to be translated from preclinical studies to clinical trials, mainly since the models are unable to replicate human pathophysiology (e.g.: cerebral vasospasm and delayed cerebral ischemia) [108].

Current preclinical SAH models

To better understand areas of possible improvement, it is important to understand the main types of SAH models available. Currently, even though most SAH occur via spontaneous rupture of cerebral aneurysms, most rodent models mimic non-aneurysmal SAH [109]. This is because it is difficult to induce cerebral aneurysms in rodents, which is a significant challenge that will be elaborated herein [108, 110]. Non-aneurysmal SAH models are mainly created via two methods: (1) prechiasmatic and cisterna magna blood injection models or (2) endovascular perforation [108]. These models are widely used, as evidenced by a recent study that used them to test mesenchymal stem cells-derived therapies for SAH as well [111].

Aneurysm induction in animal models

However, it is important to distinguish non-aneurysmal SAH models from aSAH models (Figure 2). Not only because aSAH represents a majority of human SAH cases, but also because aSAH has additional consequences, as previously described, of endothelial and inflammatory changes due to the spontaneous rupture of an intracranial aneurysm [108]. Without true aSAH models, it is hard to evaluate preventative and/or therapeutic paradigms in experimental models [108]. To tackle this challenge, efforts have focused on trying to induce aneurysms in rodent models through a few methods. First, hypertension and hemodynamic stress has been shown to induce aneurysms, but this method can take up to three months and the resulting aneurysms are small [110, 112]. Another method is to inject elastase to degrade internal and external lamina of cerebral vessels, which results in aneurysms in approximately three weeks [113–115]. This triad of hypertension, hemodynamic stress, and elastase injections has been used to develop the first intracranial aneurysm mouse model [116]. C57BL/6J mice were injected with elastase at the right basal cistern and continuously infused with angiotensin-II to produce the desired hypertension and hemodynamic stress [11, 108]. This method resulted in 500 μm intracranial aneurysms (dose-dependent on concentration of elastase and angiotensin-II) [108]. The use of angiotensin-II has been supported by the attenuation of aneurysm rupture while using angiotensin I-converting enzyme (ACE) inhibitors [112].

While the aforementioned triad model was effective in inducing aneurysms, it utilized angiotensin-II, which may cause confounding systemic effects due to inflammation and reactive oxygen species within vessel walls [117]. Thus, one factor to keep in mind is the hypertensive agent that is utilized [108]. An alternative compound is deoxycorticosterone acetate (DOCA). The original methodology included a DOCA pellet being implanted post unilateral nephrectomy along with an elastase injection and 1% saline drinking intake [118].
While this method resulted in intracranial aneurysm rupture in the circle of Willis between 7–16 days, the unilateral nephrectomy posed the problem of depleting blood pressure affecting hormones, such as renin and others [117]. Thus, a newly proposed idea is to implant DOCA and 1% saline without nephrectomy, although this has not been investigated yet in the setting of cerebral aneurysms [108].

**Future directions for preclinical studies**

Given the summary of current SAH models, there are still areas of improvement needed mainly because the current models do not allow for studying long-term outcomes and known complications of aSAH, including cerebral vasospasm and/or delayed cerebral ischemia [108]. Starting with cerebral vasospasm, several methods exist to examine this (histological analysis to measure intraluminal diameter and gel casting of cerebral vasculature), but require sacrificing rodents, preventing the study of long-term outcomes or the progression of cerebral vasospasm [119–121]. In vivo imaging, such as synchrotron radiation angiography and digital subtraction angiography, has been used to study rodent cerebral vessels to avoid this issue [122]. However, use of angiography is quite limited due to the toxicity of contrast agents. A research study in 2005 turned to using MRA to overcome the lack of utilizing serial angiography images, which produced similar results to previous methods [123]. But this also posed new concerns in that the technique is quite time consuming, expensive, and requires anesthesia, which can affect the SAH pathophysiology [108]. Thus, there isn’t an ideal method of studying cerebral vasospasm currently and would be a good area of future research.

Another complication of aSAH with limited investigation via preclinical models is delayed cerebral ischemia (DCI). A systematic review of 78 preclinical studies showed that only 38% of models (with the most prevalent method being cisterna magna injection) reproduced DCI, but these instances were never investigated with imaging [124]. Given that DCI is a major prognostic factor of poor outcomes or disability after aSAH, it is imperative to find a preclinical model that reproduces DCI well [124, 125].

To summarize, the current models for aSAH do not allow for translation to clinical trials due to difficulty of inducing spontaneous aneurysmal rupture, the lack of temporal control, the inability to follow long-term outcomes, and the limited ability to study the severity and progression of noted complications of aSAH such as cerebral vasospasm, delayed cerebral ischemia (DCI), early brain injury, and neurological deficits [108, 126]. Thus, the goal should be to create a model that encompasses all these aspects. Future research efforts, beyond the forementioned points, should also focus on creating a standardized protocol/preclinical model so that comparison of results across studies can be more easily facilitated.

**Future directions and conclusion**

In a patient with an aSAH due to a ruptured intracranial aneurysm, the initial goal is stabilization of the patient in which their hemodynamic status and ability to protect their airway is assessed [127]. Once this is accomplished, treatment options of the inciting vascular defect can be addressed. Generally, two different methods exist for treatment of an intracranial aneurysm leading to SAH, either microsurgical clipping or endovascular
coiling [128]. The choice of which treatment to pursue depends on anatomical factors such as the location of the affected artery, characteristics of the aneurysm, the characteristics of the hemorrhage and its subsequent mass effect [25]. Beyond the anatomy of the vascular injury, other factors that are considered when choosing a method of treatment are the overall health of the patient and they able to undergo invasive surgery, as well as the preference and comfort level of the neurosurgeon providing treatment [127]. Regardless of what treatment method is chosen, providing treatment in a timely fashion remains of utmost importance with the goal of preventing rebleeding [25, 129].

Microsurgical repair of aneurysmal SAH once was the primary means of repair prior to the development of specialized endovascular repair methods [130]. Surgical repair is an invasive method of aneurysm repair and thus confers greater risk intraoperatively and postoperatively than endovascular repair. It entails performing a craniotomy and visualizing the aneurysm while evacuating the extravasated blood. The aneurysm is then mechanically occluded using titanium clips while care is taken to preserve blood flow through the adjacent arteries [131]. Due to the invasive nature of the procedure, it has fallen out of favor when compared to endovascular repair. Additionally, endovascular coiling is a means of aneurysm repair in patients that are poorer surgical candidates such as those that are older or have cardiovascular comorbidities. Prior to the endovascular intervention, neuroimaging is conducted to ensure that there is no hydrocephalus, hemorrhage or recent infarction [132]. The procedure entails catheter insertion using fluoroscopic guidance. Metal coils are then placed in the lumen of the aneurysm with the goal of interrupting blood flow to the aneurysm while acting as a nidus for thrombotic occlusion of the aneurysm.

Neuroinflammation plays a critical process in both aneurysm rupture, injury progression, and ultimately the healing process. It is still a topic that is poorly understood but has significant clinical relevance. In this review, we looked at the role of inflammatory cytokines and contribution to vasospasm and hydrocephalus. Pre-clinical literature provided important guidance on important pathways and the inflammatory surge. We also presented further guidance regarding areas of needed investigation. This is a topic that will gain ongoing relevance in the quest for improved treatment options.

**Abbreviations**

- aSAH: aneurysmal subarachnoid hemorrhage
- NF-κB: transcription factor-κB
- BBB: blood-brain barrier
- CRP: C-reactive protein
- CSF: cerebrospinal fluid
- DCI: delayed cerebral ischemia
- SAH: subarachnoid hemorrhage
- DOCA: deoxycorticosterone acetate
ET-1  endothelin 1
HMGB1  high mobility group box 1
EVD  external ventricular drain
HMGB1  high-mobility group box-1
ICAM-1  intercellular adhesion molecule-1
MAC  membrane attack complex
MFG-E8  milk fat globule epidermal growth factor 8
MMP-9  matrix metalloproteinase-9
NF-κB  nuclear factor kappa B
TGFβ1  transforming growth factor beta-1
ACE  angiotensin I-converting enzyme
VCAM-1  vascular cell adhesion molecule-1
BMI  body mass index

References

1. Juvela S Prevalence of and risk factors for intracranial aneurysms. Lancet Neurol. 2011;10(7):595–597 10.1016/S1474-4422(11)70125-9 [PubMed: 21641283]
2. Lucke-Wold BP, Logsdon AF, Manoranjan B, et al. Aneurysmal subarachnoid hemorrhage and neuroinflammation: a comprehensive review. Int J Mol Sci. 2016;17(4):497. 10.3390/ijms17040497 [PubMed: 27049383]
3. Penn DL, Komotar RJ, Sander Connolly E. Hemodynamic mechanisms underlying cerebral aneurysm pathogenesis. J Clin Neurosci. 2011;18(11):1435–1438. 10.1016/j.jocn.2011.05.001 [PubMed: 21917457]
4. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, Klinger K, Arnaout MA. Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci U S A. 2000;97(4):1731–1736. 10.1073/pnas.040550097 [PubMed: 10677526]
5. Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):40–47. 10.1002/ajmg.c.31553 [PubMed: 28306228]
6. Wang Z, Kolega J, Hoi Y, et al. Molecular alterations associated with aneurysmal remodeling are localized in the high hemodynamic stress region of a created carotid bifurcation. Neurosurgery. 2009;65(1):169–178. 10.1227/01.NEU.0000343541.85713.01 [PubMed: 19574839]
7. Tulamo R, Frösen J, Hernesniemi J, Niemelä M. Inflammatory changes in the aneurysm wall: a review. J Neurointerv Surg. 2010;2(2):120–130. 10.1136/jnis.2009.002055 [PubMed: 21990591]
8. Pawlowska E, Szczepanska J, Wisniewski K, Tokarz P, Jaskólski DJ, Blasiak J. NF-κB-mediated inflammation in the pathogenesis of intracranial aneurysm and subarachnoid hemorrhage. Does autophagy play a role? Int J Mol Sci. 2018;19(4):1245. 10.3390/ijms19041245
9. Aoki T, Kataoka H, Ishibashi R, Nozaki K, Morishita R, Hashimoto N. Reduced Collagen Biosynthesis Is the Hallmark of Cerebral Aneurysm: contribution of interleukin-1beta and nuclear factor-kappaB. Arterioscler Thromb Vase Biol. 2009;29(7):1080–1086. 10.1161/ATVBAHA.108.180760 [PubMed: 19359664]
10. Aoki T, Kataoka H, Shimamura M, et al. NF-κB is a key mediator of cerebral aneurysm formation. Circulation. 2007;116(24):2830–2840. 10.1161/CIRCULATIONAHA.107.728303 [PubMed: 18025535]

11. Nuki Y, Matsumoto MM, Tsang E, et al. Roles of macrophages in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab. 2009;29(3):495–503. 10.1038/jcbfm.2008.136 [PubMed: 19002198]

12. Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front Immunol. 2019;10:1084. 10.3389/fimmu.2019.01084 [PubMed: 31178859]

13. Nowicki KW, Hosaka K, Walch FJ, Scott EW, Hoh BL. M1 macrophages are required for murine cerebral aneurysm formation. J Neurointerv Surg. 2018;10(1):93–97. 10.1136/neurintsurg-2016-012911 [PubMed: 28196918]

14. Tulamo R, Frösen J, Junnikkala S, et al. Complement activation associates with saccular cerebral artery aneurysm wall degeneration and rupture. Neurosurgery. 2006;59(5):1069–1077. 10.1227/01.NEU.0000245598.84698.26 [PubMed: 17016232]

15. Friedrich V, Flores R, Sehba FA. Cell death starts early after subarachnoid hemorrhage. Neurosci Lett. 2012;512(1):6–11. 10.1016/j.neulet.2012.01.036 [PubMed: 22306092]

16. Sun Q, Wu W, Hu YC, et al. Early release of high-mobility group box 1 (HMGB1) from neurons in experimental subarachnoid hemorrhage in vivo and in vitro. J Neuroinflammation. 2014;11:106. 10.1186/1742-2094-11-106 [PubMed: 24924349]

17. Lublinsky S, Major S, Kola V, et al. Early blood-brain barrier dysfunction predicts neurological outcome following aneurysmal subarachnoid hemorrhage. EBioMedicine. 2019;43:460–472. 10.1016/j.ebiom.2019.04.054 [PubMed: 31162113]

18. Huang XP, Peng JH, Pang JW, et al. Peli1 contributions in microglial activation, neuroinflammatory responses and neurological deficits following experimental subarachnoid hemorrhage. Front Mol Neurosci. 2017;10:398. 10.3389/fnmol.2017.00398 [PubMed: 29249938]

19. Li R, Liu WC, Yin J, et al. TSG-6 attenuates inflammation-induced brain injury via modulation of microglial polarization in SAH rats through the SOCS3/STAT3 pathway. J Neuroinflammation. 2018;15:231. 10.1186/s12974-018-1279-1 [PubMed: 30126439]

20. Xu Z, Shi WH, Xu LB, et al. Resident microglia activate before peripheral monocyte infiltration and p75NTR blockade reduces microglial activation and early brain injury after subarachnoid hemorrhage. ACS Chem Neurosci. 2019;10(1):412–423. 10.1021/acschemneuro.8b00298 [PubMed: 30117729]

21. Heinz R, Brandenburg S, Nieminen-Kelhä M, et al. Microglia as target for anti-inflammatory approaches to prevent secondary brain injury after subarachnoid hemorrhage (SAH). J Neuroinflammation. 2021;18:36. 10.1186/s12974-021-02085-3 [PubMed: 33516246]

22. Han M, Cao Y, Guo X, et al. Mesenchymal stem cell-derived extracellular vesicles promote microglial M2 polarization after subarachnoid hemorrhage in rats and involve the AMPK/NF-κB signaling pathway. Biomed Pharmacother. 2021;133:111048. 10.1016/j.biopha.2020.111048 [PubMed: 33378955]

23. Hanafy KA. The role of microglia and the TLR4 pathway in neuronal apoptosis and vasospasm after subarachnoid hemorrhage. J Neuroinflammation. 2013;10:868. 10.1186/1742-2094-10-83

24. Wong GK, Boet R, Ng SC, et al. Ultra-early (within 24 hours) aneurysm treatment after subarachnoid hemorrhage. World Neurosurg. 2012;77(2):311–315. 10.1016/j.wneu.2011.09.025 [PubMed: 22120257]

25. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711–1737. 10.1161/STR.0b013e3182587839 [PubMed: 22556195]

26. Matias-Guiu JA, Serna-Candel C. Early endovascular treatment of subarachnoid hemorrhage. Interv Neurol. 2013;1:56–64. 10.1159/000346768 [PubMed: 25187768]

27. Nieminen MS, Fruhwald S, Heunks LM, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel. 2013;5(4):227–245. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868185/ [PubMed: 24364017]
28. Wanderer S, Andereggen L, Mrosek J, et al. Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid hemorrhage. J Neurointerv Surg. 2022;14(4):408–412. 10.1136/neurintsurg-2021-017504 [PubMed: 34039684]

29. Kranich J, Krautler NJ, Heinen E, et al. Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J Exp Med. 2008;205(6):1293–1302. 10.1084/jem.20071019 [PubMed: 18490487]

30. Deroide N, Li X, Lerouet D, et al. MFGES inhibits inflammasome-induced IL-1β production and limits postischemic cerebral injury. J Clin Invest. 2013;123(3):1176–1181. 10.1172/JCI65167 [PubMed: 23454767]

31. Qiu JX, Li WN, Mu RT, Wang LL, Guo L, Ma LL. MFGES decreased neuronal apoptosis and neuroinflammation to ameliorate early brain injury induced by subarachnoid hemorrhage through the inhibition of HMGB1. Hum Exp Toxicol. 2022;41:9603271221093635

32. Haruma J, Teshigawara K, Hishikawa T, et al. Anti-high mobility group box-1 (HMGB1) antibody attenuates delayed cerebral vasospasm and brain injury after subarachnoid hemorrhage in rats. Sci Rep. 2016;6:37755. 10.1038/srep37755 [PubMed: 27883038]

33. An JY, Pang HG, Huang TQ, et al. AG490 ameliorates early brain injury via inhibition of JAK2/STAT3-mediated regulation of HMGB1 in subarachnoid hemorrhage. Exp Ther Med. 2018;15(2):1330–1338. 10.3892/etm.2017.5539 [PubMed: 29434719]

34. Wei CC, Guo SQ, Liu WC, et al. Resolvin D1 ameliorates Inflammation-Mediated Blood-Brain Barrier Disruption After Subarachnoid Hemorrhage in rats by Modulating A20 and NLRP3 Inflammasome. Front Pharmacol. 2021;11:610734. 10.3389/fphar.2020.610734 [PubMed: 33732145]

35. Mathiesen T, Andersson B, Lothenius A, von Holst H. Increased interleukin-6 levels in cerebrospinal fluid following subarachnoid hemorrhage. J Neurosurg. 1993;78(4):562–567. 10.3171/jns.1993.78.4.0562 [PubMed: 8450329]

36. Kikuchi T, Okuda Y, Kaito N, Abe T. Cytokine production in cerebrospinal fluid after subarachnoid haemorrhage. Neurol Res. 1995;17(2):106–108. 10.1080/01616412.1995.11740296 [PubMed: 7609845]

37. Mathiesen T, Edner G, Ulfarsson E, Andersson B. Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-alpha following subarachnoid hemorrhage. J Neurosurg. 1997;87(2):215–220. 10.3171/jns.1997.87.2.0215 [PubMed: 9254084]

38. Osuka K, Suzuki Y, Tanazawa T, et al. Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien). 1998;140:943–951. 10.1007/s007010050197 [PubMed: 9842432]

39. Gruber A, Rössler K, Graninger W, Donner A, Illievich MU, Czech T. Ventricular cerebrospinal fluid serum concentrations of sTNFR-I, IL-1ra, and IL-6 after aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2000;12(4):297–306. 10.1097/00008506-200010000-00001 [PubMed: 11473777]

40. Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry. 2001;70(4):534–537. 10.1136/jnnp.70.4.534 [PubMed: 11254783]

41. Takizawa T, Tada T, Kitazawa K, et al. Inflammatory cytokine cascade released by leukocytes in cerebrospinal fluid after subarachnoid hemorrhage. Neurol Res. 2001;23(7):724–730. 10.1179/016164101101199243 [PubMed: 11680512]

42. Kwon KY, Jeon BC. Cytokine levels in cerebrospinal fluid and delayed ischemic deficits in patients with aneurysmal subarachnoid hemorrhage. J Korean Med Sci. 2001;16(6):774–780. 10.3346/jkms.2001.16.6.774 [PubMed: 11748361]

43. Hendryk S, Jarzab B, Josko J. Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett. 2004;25(1–2):141–147. https://pubmed.ncbi.nlm.nih.gov/15159698

44. Nakahara T, Tsuruta R, Kaneko T, et al. High-mobility group box 1 protein in CSF of patients with subarachnoid hemorrhage. Neurocrit Care. 2009;11:362–368. 10.1007/s12028-009-9276-y [PubMed: 19777384]
45. Sarrafzadeh A, Schlenk F, Gericke C, Vajkoczy P. Relevance of cerebral interleukin-6 after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2010;13:339–346. 10.1007/s12028-010-9432-4 [PubMed: 20725805]

46. Graetz D, Nagel A, Schlenk F, Sakowitz O, Vajkoczy P, Sarrafzadeh A. High ICP as trigger of proinflammatory IL-6 cytokine activation in aneurysmal subarachnoid hemorrhage. Neurol Res. 2010;32(7):728–735. 10.1179/16164109124646122650 [PubMed: 19682408]

47. Hanafy KA, Grobelny B, Fernandez L, et al. Brain interstitial fluid TNF-alpha after subarachnoid hemorrhage. J Neurol Sci. 2010;291(1–2):69–73. 10.1016/j.jns.2009.12.023 [PubMed: 20110094]

48. Mellergård P, Åneman O, Sjögren F, Säberg C, Hillman J. Differences in cerebral extracellular response of interleukin-1β, interleukin-6, and interleukin-10 after subarachnoid hemorrhage or severe head trauma in humans. Neurosurgery. 2011;68(1):12–19. 10.1227/NEU.0b013e3181ef2a40 [PubMed: 21150751]

49. Sokół B, Woźniak A, Jankowski R, et al. HMGB1 level in cerebrospinal fluid as a marker of treatment outcome in patients with acute hydrocephalus following aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2015;24(8):1897–1904. 10.1016/j.jstrokecerebrovasdis.2015.05.002 [PubMed: 26047599]

50. Höllig A, Remmel D, Stoffel-Wagner B, Schubert GA, Clusmann H. Association of early inflammatory parameters after subarachnoid hemorrhage with functional outcome: a prospective cohort study. Clin Neurol Neurosurg. 2015;138:84–88. 10.1016/j.clineuro.2015.08.030 [PubMed: 2635810]

51. Niwa A, Osuka K, Nakura T, Matsuo N, Watabe T, Takayasu M. Interleukin-6, MCP-1, IP-10, and MIG are sequentially expressed in cerebrospinal fluid after subarachnoid hemorrhage. J Neuroinflammation. 2016;13:217. 10.1186/s12974-016-0675-7 [PubMed: 27576738]

52. Wu W, Guan Y, Zhao G, et al. Elevated IL-6 and TNF-α levels in cerebrospinal fluid of subarachnoid hemorrhage patients. Mol Neurobiol. 2016;53:3277–3285. 10.1007/s12035-015-9268-1 [PubMed: 26063595]

53. Chaudhry SR, Stoffel-Wagner B, Kinfe TM, et al. Elevated systemic IL-6 levels in patients with aneurysmal subarachnoid hemorrhage is an unspecific marker for post-SAH complications. Int J Mol Sci. 2017;18(12):2580. 10.3390/ijms18122580

54. García JM, Stillings SA, Leclerc JL, et al. Role of interleukin-10 in acute brain injuries. Front Neurol. 2017;8:244. 10.3389/fneur.2017.00244 [PubMed: 28659854]

55. Šturiš K, Neuman E, Vybíhal V, et al. Early dynamics of interleukin-6 in cerebrospinal fluid after aneurysmal subarachnoid hemorrhage. J Neurol Surg A Cent Eur Neurosurg. 2018;79:612–618. 10.1016/j.jns.2018.05.006 [PubMed: 29192994]

56. Lv SY, Wu Q, Liu JP, et al. Levels of interleukin-1β, interleukin-18, and tumor necrosis factor-α in cerebrospinal fluid of aneurysmal subarachnoid hemorrhage patients may be predictors of early brain injury and clinical prognosis. World Neurosurg. 2018;112:362–373. 10.1016/j.wneu.2017.12.076 [PubMed: 29277532]

57. Vlachogiannis P, Hillered L, Khalil F, Enblad P, Ronne-Engström E. Interleukin-6 levels in cerebrospinal fluid and plasma in patients with severe spontaneous subarachnoid hemorrhage. World Neurosurg. 2019;122:612–618. 10.1016/j.wneu.2018.10.113 [PubMed: 30814021]

58. Chaudhry SR, Kahler UT, Kinfe TM, et al. Elevated systemic IL-10 levels indicate immunodepression leading to nosocomial infections after aneurysmal subarachnoid hemorrhage (SAH) in patients. Int J Mol Sci. 2020;21(5):1569. 10.3390/ijms21051569

59. Ridwan S, Grote A, Simon M. Interleukin 6 in cerebrospinal fluid is a biomarker for delayed cerebral ischemia (DCI) related infarctions after aneurysmal subarachnoid hemorrhage. Sci Rep. 2021;11:12. 10.1038/s41598-020-79586-3 [PubMed: 33420113]

60. Coulilbaly AP, Provenceco JJ. Aneurysmal subarachnoid hemorrhage: an overview of inflammation-induced cellular changes. Neurotherapeutics. 2020;17:436–445. 10.1007/s13311-019-00829-x [PubMed: 31907877]

61. Zeiler FA, Thelin EP, Czosnyka M, Hutchinson PJ, Monen DK, Helmy A. Cerebrospinal fluid and microdialysis cytokines in aneurysmal subarachnoid hemorrhage: a scoping systematic review. Front Neurol. 2017;8:379. 10.3389/fneur.2017.00379 [PubMed: 28848487]
62. Vlachogiannis P, Hillered L, Enblad P, Ronne-Engström E. Temporal patterns of inflammation-related proteins measured in the cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage using multiplex Proximity Extension Assay technology. PLoS One. 2022;17(3):e0263460. 10.1371/journal.pone.0263460 [PubMed: 35324941]

63. Giulian D, Baker TJ, Shih LC, Lachman LB. Interleukin 1 of the central nervous system is produced by ameboid microglia. J Exp Med. 1986;164(2):594–604. 10.1084/jem.164.2.594 [PubMed: 3487617]

64. Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 1989;491(2):394–397. 10.10160006-8993(89)90078-4 [PubMed: 2765895]

65. Aloisi F, Carè A, Borsellino G, et al. Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J Immunol. 1992;149(7):2358–2366. https://pubmed.ncbi.nlm.nih.gov/1382099 [PubMed: 1382099]

66. Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke. 2000;31(12):2971–2975. 10.116101.STR.31.12.2971 [PubMed: 11108758]

67. Weiland J, Beez A, Westermaier T, Kunze E, Sirén AL, Lilla N. Neuroprotective strategies in aneurysmal subarachnoid hemorrhage (aSAH). Int J Mol Sci. 2021;22(11):5442. 10.3390/ijms22115442 [PubMed: 34064048]

68. Charpentier C, Audibert G, Guillemin F, et al. Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurysmal subarachnoid hemorrhage. Stroke. 1999;30(7):1402–1408. 10.116101.STR.30.7.1402 [PubMed: 10390314]

69. Juvela S, Siironen J, Kuhmonen J. Hyperglycemia, excess weight, and history of hypertension as risk factors for poor outcome and cerebral infarction after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2005;102(6):998–1003. 10.3171/jns.2005.102.6.0998 [PubMed: 16028757]

70. Macdonald RL, Rosengart A, Huo D, Karrison T. Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99(4):644–652. 10.1227/01.STR.01.0000000000.0000000093 [PubMed: 14567598]

71. McGirt MJ, Mavropoulos JC, McGirt LY, et al. Leukocytosis as an independent risk factor for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;98(6):1222–1226. 10.1016/j.jns.2003.98.6.1222 [PubMed: 12816268]

72. Wilkins RH. Cerebral vasospasm. Crit Rev Neurobiol. 1990;6(1):51–77. https://pubmed.ncbi.nlm.nih.gov/2225095 [PubMed: 2225095]

73. Kramer AH, Mikolaenko I, Deis N, et al. Intraventricular hemorrhage volume predicts poor outcomes but not delayed ischemic neurological deficits among patients with ruptured cerebral aneurysms. Neurosurgery. 2010;67(4):1044–1053. 10.1227/NEU.0b013e318131e1d379 [PubMed: 20881568]

74. Kolias AG, Sen J, Belli A. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. J Neurosci Res. 2009;87(1):1–11. 10.1002/jnr.21823 [PubMed: 18709660]

75. Horowitz A, Menice CB, Laporte R, Morgan KG. Mechanisms of smooth muscle contraction. Physiol Rev. 1996;76(4):967–1003. 10.1152/physrev.1996.76.4.967 [PubMed: 8874491]

76. Kim P, Yoshimoto Y, Iino M, Tomio S, Kirino T, Nonomura Y. Impaired calcium regulation of smooth muscle during chronic vasospasm following subarachnoid hemorrhage. J Cereb Blood Flow Metab. 1996;16(2):334–341. 10.1097/00004647-199603000-00020 [PubMed: 8594067]
80. Rubanyi GM. Endothelium-derived relaxing and contracting factors. J Cell Biochem. 1991;46(1):27–36. 10.1002/jcb.240460106 [PubMed: 1874796]

81. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 1999;61:391–415. 10.1146/annurev.physiol.61.1.391 [PubMed: 10099694]

82. Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther. 2005;105(1):23–56. 10.1016/j.pharmthera.2004.10.002 [PubMed: 15626454]

83. Barth M, Capelle HH, Münch E, et al. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage – preliminary results from a randomized clinical series. Acta Neurochir (Wien). 2007;149(9):911–918. 10.1007/s00701-007-1249-3 [PubMed: 17700991]

84. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10(7):618–625. 10.1016/S1474-4422(11)70108-9 [PubMed: 21640651]

85. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015–3021. 10.1161/STROKEAHA.108.519942 [PubMed: 18688013]

86. Grote E and Hassler W, “The critical first minutes after subarachnoid hemorrhage,” (in eng), Neurosurgery, vol. 22, no. 4, pp. 654–61, Apr 1988, doi: 10.1227/00006123-19880400-00006. 10.1227/00006123-19880400-00006 [PubMed: 3287211]

87. Naredi S et al. , “Increased sympathetic nervous activity in patients with nontraumatic subarachnoid hemorrhage,” Stroke, vol. 31, no. 4, pp. 901–6, Apr 2000, doi: 10.1161/01.str.31.4.901. 10.1161/01.STR.31.4.901 [PubMed: 10753996]

88. Di Battista AP, Rizoli SB, Lejnieks B, et al. Sympathoadrenal activation is associated with acute traumatic coagulopathy and endotheliopathy in isolated brain injury. Shock. 2016;46(3 Suppl 1):96–103. 10.1097/SHK.0000000000000642 [PubMed: 27206278]

89. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337–341. 10.1038/nature14432 [PubMed: 26030524]

90. Sun BL, Xie FM, Yang MF, et al. Blocking cerebral lymphatic drainage deteriorates cerebral oxidative injury in rats with subarachnoid hemorrhage. Acta Neurochir Suppl. 2011;110(Pt 2):49–53. 10.1007/978-3-7091-0356-2_10

91. Louveau A, Plog BA, Antila S, Alitalo K, Nedergaard M, Kipnis J. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest. 2017;127(9):3210–3219. 10.1172/JCI90603 [PubMed: 28862640]

92. Luo C, Yao X, Li J, et al. Paravascular pathways contribute to vasculitis and neuroinflammation after subarachnoid hemorrhage independently of glymphatic control. Cell Death Dis. 2016;7(3):e2160. 10.1038/cddis.2016.63 [PubMed: 27031957]

93. Gaberel T, Gakuba C, Goulay R, et al. Impaired glymphatic perfusion after strokes revealed by contrast-enhanced MRI: a new target for fibrinolysis? Stroke. 2014;45(10):3092–3096. 10.1161/STROKEAHA.114.006617 [PubMed: 25190438]

94. Yoshioka H, Inagawa T, Tokuda Y, Inokuchi F. Chronic hydrocephalus in elderly patients following subarachnoid hemorrhage. Surg Neurol. 2000;53(2):119–125. 10.1016/S0080-9039(99)00185-8 [PubMed: 10713188]

95. de Oliveira JG, Beck J, Setzer M, et al. Risk of shunt-dependent hydrocephalus after occlusion of ruptured intracranial aneurysms by surgical clipping or endovascular coiling: a single-institution series and meta-analysis. Neurosurgery. 2007;61(5):924–934. 10.1227/01.neu.0000303188.72425.24 [PubMed: 18091269]

96. Yang TC, Chang CH, Liu YT, Chen YL, Tu PH, Chen HC. Predictors of shunt-dependent chronic hydrocephalus after aneurysmal subarachnoid haemorrhage. Eur Neurol. 2013;69(5):296–303. 10.1159/000346119 [PubMed: 23445755]
97. Qian C, Yu X, Chen J, et al. Effect of the drainage of cerebrospinal fluid in patients with aneurismal subarachnoid hemorrhage: a meta-analysis. Medicine (Baltimore). 2016;95(41):e5140. 10.1097/MD.00000000000005140 [PubMed: 27741143]

98. Basaldella L, Marton E, Fiorindi A, Scarpa B, Badreddine H, Longatti P. External ventricular drainage alone versus endoscopic surgery for severe intraventricular hemorrhage: a comparative retrospective analysis on outcome and shunt dependency. Neurosurg Focus. 2012;32(4):E4. 10.3171/2012.1.FOCUS11349

99. Dóczi T, Nemessányi Z, Szegváry Z, Huszka E. Disturbances of cerebrospinal fluid circulation during the acute stage of subarachnoid hemorrhage. Neurosurgery. 1983;12(4):435–438. 10.1227/00006123-19830400-00011 [PubMed: 6856069]

100. Czorlich P, Ricklefs F, Reitz M, et al. Impact of intraventricular hemorrhage measured by Graeb and LeRoux score on case fatality risk and chronic hydrocephalus in aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2015;157(3):409–415. 10.1007/s00701-014-2334-z [PubMed: 25599911]

101. Golanov EV, Bovshik EI, Wong KK, et al. Subarachnoid hemorrhage – induced block of cerebrospinal fluid flow: role of brain coagulation factor III (tissue factor). J Cereb Blood Flow Metab. 2018;38(5):793–808. 10.1177/0271678X17701157 [PubMed: 28350198]

102. Liu F, Yuan W, Liao DG, Zhang ZF, Liang YT, Wang ZF. [Association of chronic hydrocephalus after aneurysmal subarachnoid hemorrhage with transforming growth factor-β1 levels and other risk factors]. J South Med Univ. 2013;33(3):382–385. 10.3969/j.issn.1673-4254.2013.03.15

103. Johnson MD, Jennings MT, Gold LI, Moses HL. Transforming growth factor-beta in neural embryogenesis and neoplasia. Hum Pathol. 1993;24(5):457–462. 10.1016/0046-8177(93)90156-B [PubMed: 8387957]

104. Ito Y, Goldschmeding R, Kasuga H, et al. Expression patterns of connective tissue growth factor and of TGF-beta isoforms during glomerular injury recapitulate glomerulogenesis. Am J Physiol Renal Physiol. 2010;299(3):F545–F558. 10.1152/ajprenal.00120.2009 [PubMed: 20576680]

105. Dong C, Ming X, Ye Z, et al. Icariside II attenuates chronic hydrocephalus in an experimental subarachnoid hemorrhage rat model. J Pharm Pharm Sci. 2018;21(1):318–325. 10.18433/jpps29811 [PubMed: 30079091]

106. Marbacher S, Grüter B, Schönig S, et al. Systematic review of in vivo animal models of subarachnoid hemorrhage: species, standard parameters, and outcomes. Transl Stroke Res. 2019;10:250–258. 10.1007/s12975-018-0657-4

107. Strange F, Gruter BE, Fandino J, Marbacher S. Preclinical intracranial aneurysm models: a systematic review. Brain Sci. 2020;10(3):134. 10.3390/brainsci10030134

108. Leclerc JL, Garcia JM, Diller MA, et al. A comparison of pathophysiology in humans and rodent models of subarachnoid hemorrhage. Front Mol Neurosci. 2018;11:71. 10.3389/fnmol.2018.00071 [PubMed: 29623028]

109. Marder CP, Narla V, Fink JR, Tozer Fink KR. Subarachnoid hemorrhage: beyond aneurysms. AJR Am J Roentgenol. 2014;202(1):25–37. 10.2214/AJR.12.9749 [PubMed: 24370126]

110. Hashimoto N, Handa H, Nagata I, Hazama F. Animal model of cerebral aneurysms: pathology and pathogenesis of induced cerebral aneurysms in rats. Neurol Res. 1984;6(1–2):33–40. 10.1080/01616412.1984.11739661 [PubMed: 6147777]

111. He JL, Liu JY, Huang Y, Lan ZW, Tang XQ, Hu ZP. Mesenchymal stem cells-derived therapies for subarachnoid hemorrhage in preclinical rodent models: a meta-analysis. Stem Cell Res Ther. 2022;13:42. 10.1186/s13287-022-02725-2 [PubMed: 35093176]

112. Li Q, Lv FJ, Yao GE, Li YM, Xie P. 64-section multidetector CT angiography for evaluation of intracranial aneurysms: comparison with 3D rotational angiography. Acta Radiol. 2014;55(7):840–846. 10.1177/0284185113506138 [PubMed: 24065201]

113. Starke RM, Chalouhi N, Ding D, et al. Vascular smooth muscle cells in cerebral aneurysm pathogenesis. Transl Stroke Res. 2014;5:338–346. 10.1007/s12975-013-0290-1 [PubMed: 24323713]

114. Hosaka K, Hoh BL. Inflammation and cerebral aneurysms. Transl Stroke Res. 2014;5:190–198. 10.1007/s12975-013-0313-y [PubMed: 24323732]
115. Shimada R, Nemoto S, Ozawa H, Katsumata T. Surgical treatment of a mycotic pseudoaneurysm of the transverse arch using a rifampicin-impregnated dacron patch in an infant. J Card Surg. 2015;30(3):281–283. 10.1111/jocs.12492 [PubMed: 25496762]

116. Wada K, Makino H, Shimada K, Shikata F, Kuwabara A, Hashimoto T. Translational research using a mouse model of intracranial aneurysm. Transl Stroke Res. 2014;5:248–251. 10.1007/s12975-013-0296-8 [PubMed: 24323719]

117. Tada Y, Wada K, Shimada K, et al. Roles of hypertension in the rupture of intracranial aneurysms. Stroke. 2014;45(2):579–586. 10.1161/STROKEAHA.113.003072 [PubMed: 24370755]

118. Wada K, Hattori K, Araki Y, et al. [A case of moyamoya disease with a subarachnoid hemorrhage treated with endovascular technique]. No Shinkei Geka. 2014;42(11):1027–1033. 10.1147/nf.1436200026 [PubMed: 25351798]

119. Raslan F, Albert-Weißenberger C, Westermaier T, Saker S, Kleinschnitz C, Lee JY. A modified double injection model of cisterna magna for the study of delayed cerebral vasospasm following subarachnoid hemorrhage in rats. Exp Transl Stroke Med. 2012;4:23. 10.1186/2040-7378-4-23 [PubMed: 23194464]

120. Altay T, Smithason S, Volokh N, Rasmussen PA, Provencio JJ. A novel method for subarachnoid hemorrhage to induce vasospasm in mice. J Neurosci Methods. 2009;183(2):136–140. 10.1016/j.jneumeth.2009.06.027 [PubMed: 19576247]

121. Parra A, McGirt MJ, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: methodological analysis. Neurol Res. 2002;24(5):510–516. 10.1179/016164102101200276 [PubMed: 12117325]

122. Cai J, Sun YH, Yuan FL, et al. A novel intravital method to evaluate cerebral vasospasm in rat models of subarachnoid hemorrhage: a study with synchrotron radiation angiography. PLoS One. 2012;7(3):e33366. 10.1371/journal.pone.0033366 [PubMed: 22428033]

123. van den Bergh WM, Schepers J, Veldhuis WB, Nicolay K, Tulleken CA, Rinkel GJ. Magnetic resonance imaging in experimental subarachnoid haemorrhage. Acta Neurochir (Wien). 2005;147(9):977–983. 10.1007/s00701-005-0539-x [PubMed: 15900401]

124. Goursaud S, Martinez de Lizarrondo S, Grollou F, et al. Delayed cerebral ischemia after subarachnoid hemorrhage: is there a relevant experimental model? a systematic review of preclinical literature. Front Cardiovasc Med. 2021;8:752769. 10.3389/fcvm.2021.752769 [PubMed: 34896959]

125. Geraghty JR, Testai FD. Delayed cerebral ischemia after subarachnoid hemorrhage: beyond vasospasm and towards a multifactorial pathophysiology. Curr Atheroscler Rep. 2017;19:50. 10.1007/s11883-017-0690-x [PubMed: 29063300]

126. Zhou J, Yang Z, Shen R, et al. Resveratrol improves mitochondrial biogenesis function and activates PGC-1α pathway in a preclinical model of early brain injury following subarachnoid hemorrhage. Front Mol Biosci. 2021;8:620683. 10.3389/fmolb.2021.620683 [PubMed: 33968980]

127. Tawk RG, Hasan TF, D’Souza CE, Peel JB, Freeman WD. Diagnosis and treatment of unruptured intracranial aneurysms and aneurysmal subarachnoid hemorrhage. Mayo Clin Proc. 2021;96(7):1970–2000. 10.1016/j.mayocp.2021.01.005 [PubMed: 33992453]

128. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306–318. 10.1016/S0140-6736(07)60153-6 [PubMed: 17258671]

129. Sharma D. Perioperative management of aneurysmal subarachnoid hemorrhage. Anesthesiology. 2020;133:1283–1305. 10.1097/ALN.0000000000003558 [PubMed: 32986813]

130. van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. Brain. 2001;124(2):249–278. 10.1093/brain/124.2.249 [PubMed: 11157554]

131. Lindgren A, Vergouwen MD, van der Schaaf I, et al. Endovascular coiling versus neurosurgical clipping for people with aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2018;8(8):CD003085. 10.1002/14651858.CD003085.pub3 [PubMed: 3010521]

132. Kirmani JF, Alkawi A, Ahmed S, et al. Endovascular treatment of subarachnoid hemorrhage. Neurol Res. 2005;27(Suppl 1):103–107. 10.1179/016164105X35521 [PubMed: 15829168]

Clin Res Commun. Author manuscript; available in PMC 2022 July 14.
Figure 1.
Inflammatory changes leading to aneurysm formation
Figure 2.
Summary of current preclinical SAH models
## Table 1
Summary of inflammatory cytokines studied in articles concerning SAH

| Paper                        | Year | IL-1ra | IL-1a | IL-1b | IL-6 | IL-8 | IL-10 | IL-18 | TNFα | ICAM-1 | HMGB-1 | TGF-b1 |
|------------------------------|------|--------|-------|-------|------|------|-------|-------|------|--------|--------|--------|
| Mathiesen et al. [35]        | 1993 | x      |       |       |      |      |       |       |      |        |        |        |
| Kikuchi et al. [36]          | 1995 | x      | x     | x     | x    | x    | x     |       |      |        |        |        |
| Mathiesen et al. [37]        | 1997 | x      | x     | x     |      |      |       | x     |      |        |        |        |
| Osuka et al. [38]            | 1998 | x      |       |       |      |      |       |       | x    |        |        |        |
| Gruber et al. [39]           | 2000 | x      | x     | x     |      |      |       |       |      |        |        | x      |
| Fassbender et al. [40]       | 2001 | x      | x     |       |      |      |       |       |      |        |        | x      |
| Takizawa et al. [41]         | 2001 | x      | x     |       | x    |      |       |       |      |        |        |        |
| Kwon et al. [42]             | 2001 | x      | x     |       |      |      |       |       | x    |        |        |        |
| Hendryk et al. [43]          | 2004 | x      | x     |       |      |      |       |       | x    |        |        |        |
| Nakahara et al. [44]         | 2009 | x      | x     |       |      |      |       | x     |      |        |        |        |
| Sarrafzadeh et al. [45]      | 2010 | x      |       |       |      |      |       |       |      |        |        |        |
| Graetz et al. [46]           | 2010 | x      |       |       |      |      |       |       |      |        |        |        |
| Hanafy et al. [47]           | 2010 | x      |       |       |      |      |       |       |      |        |        |        |
| Mellergard et al. [48]       | 2011 | x      | x     | x     |      |      |       |       |      |        |        |        |
| Sokol et al. [49]            | 2015 | x      |       |       |      |      |       |       |      |        |        | x      |
| Hollig et al. [50]           | 2015 | x      |       |       |      |      |       |       |      |        |        |        |
| Niwa et al. [51]             | 2016 | x      | x     |       |      |      |       |       |      |        |        |        |
| Wu et al. [52]               | 2016 | x      |       |       |      |      |       |       |      |        |        |        |
| Chaudhry et al. [53]         | 2017 | x      |       |       |      |      |       |       |      |        |        |        |
| Garcia et al. [54]           | 2017 | x      |       |       |      |      |       |       |      |        |        |        |
| Duris et al. [55]            | 2018 | x      | x     | x     |      |      |       |       |      |        |        |        |
| Lv et al. [56]               | 2018 | x      |       |       |      |      |       |       |      |        |        | x      |
| Vlachogiannis et al. [57]    | 2019 | x      |       |       |      |      |       |       |      |        |        |        |
| Chaudhry et al. [58]         | 2020 | x      |       |       |      |      |       |       |      |        |        |        |
| Ridwan et al. [59]           | 2021 | x      |       |       |      |      |       |       |      |        |        |        |

IL-1ra, Interleukin-1 receptor antagonist; IL-1a, interleukin-1A; ICAM-1, intercellular adhesion molecule-1; HMGB1, high-mobility group box-1; TGFb1, transforming growth factor beta-1.